Caladrius Biosciences, Inc.

[Not Yet Scheduled]
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. We currently are developing first-in-class autologous cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

Ticker:
CLBS
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
XOWNA (CLBS16) for the treatment of Coronary Microvascular Dysfunction
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided